VEGF inhibitor PTC299
Phase 1/2Terminated 0 watching 0 views this week💤 Quiet
38
Development Stage
✓
Pre-clinical2
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Kaposi's Sarcoma
Conditions
Kaposi's Sarcoma
Trial Timeline
Sep 1, 2008 → Dec 1, 2010
NCT ID
NCT00686842About VEGF inhibitor PTC299
VEGF inhibitor PTC299 is a phase 1/2 stage product being developed by PTC Therapeutics for Kaposi's Sarcoma. The current trial status is terminated. This product is registered under clinical trial identifier NCT00686842. Target conditions include Kaposi's Sarcoma.
Hype Score Breakdown
Clinical
13
Activity
8
Company
7
Novelty
4
Community
3
Clinical Trials (2)
| NCT ID | Phase | Status |
|---|---|---|
| NCT01158300 | Phase 1 | Completed |
| NCT00686842 | Phase 1/2 | Terminated |
Competing Products
5 competing products in Kaposi's Sarcoma
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| Selumetinib | AstraZeneca | Phase 1/2 | 41 |
| Lopinavir/ritonavir plus Emtricitabine/Tenofovir versus Efavirenz plus Emtricitabine/Tenofovir | Merck | Approved | 85 |
| Maraviroc | Pfizer | Phase 2 | 51 |
| 50 mg/m2 aldoxorubicin + 100 mg/m2 aldoxorubicin + 150 mg/m2 aldoxorubicin | ImmunityBio | Phase 2 | 49 |
| Tc 99m tilmanocept | Navidea Biopharmaceuticals | Phase 2 | 44 |